Picture of DBV Technologies SA logo

DBV DBV Technologies SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-22.53%
3m-17.48%
6m-55.76%
1yr-51.88%
Volume Change (%)
10d/3m+39.12%
Price vs... (%)
52w High-67.37%
50d MA-17.52%
200d MA-43.38%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-55.51%
Return on Equity-49.6%
Operating Margin-1945.77%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of DBV Technologies SA EPS forecast chart

Profile Summary

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
March 1st, 2002
Public Since
March 29th, 2012
No. of Employees
88
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
96,101,161

DBV Share Price Performance

Upcoming Events for DBV

Full Year 2023 Dbv Technologies SA Earnings Release

DBV Technologies SA Annual Shareholders Meeting

Half Year 2024 Dbv Technologies SA Earnings Release

Similar to DBV

Picture of AB Science SA logo

AB Science SA

fr flag iconEuronext - Paris

Picture of Advicenne SA logo

Advicenne SA

fr flag iconEuronext - Paris

Picture of Aelis Farma SA logo

Aelis Farma SA

fr flag iconEuronext - Paris

Picture of Boiron SA logo

Boiron SA

fr flag iconEuronext - Paris

Picture of Elsalys Biotech SA logo

Elsalys Biotech SA

fr flag iconEuronext - Paris

FAQ